Either nuclear relocalization or targeted degradation of NPM1c can result in immediate downregulation of HOX genes and promotes differentiation of AML cells [91], suggesting an alternative therapeutic way to HOX genes in human AMLs carrying NPM1 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.